On November 20, 2013 Health Canada revealed the approval of Simeprevir, known as the brand name GALEXOS, to treat hepatitis C. Janssen, the company that markets GALEXOS offered excitement for the approval of it’s once a day hepatitis C treatment. Simeprevir is designed to be administered adjunctively with both ribavirin and pegylated interferon, for the[…]
Canada Approves Simeprevir for Hepatitis C
Anti-Retroviral / Anti-HIV, Antiviral, Drug Research & Development API, FDA Priority Status, Health Canada Approved 2013 Tags: Hepatitis Cribavirin Dec 04, 2013
FDA Grants Sofosbuvir Breakthrough Therapy Designation
Anti-Retroviral / Anti-HIV, Antiviral, FDA Breakthrough Therapy Status Tags: GileadHepatitis CribavirinSofosbuvir Nov 01, 2013
The end of October 2013 saw a nod from the FDA given to Gilead’s New Drug Application for Sofosbuvir. As a greatly needed treatment for hepatitis C Sofosbuvir has proven to be effectual and tolerable in a number of studies. Sofosbuvir is marketed by Gilead Science, Inc. and is clearly set up for success in[…]
Breaking News – Sofosbuvir and Ribavirin Team Up to Cure Hepatitis C
Anti-Retroviral / Anti-HIV Tags: Hepatitis CribavirinSofosbuvir Aug 29, 2013
A report in the Journal of the American Medical Association on August 28, 2013 offered exciting news for patients with Hepatitis C. A phase 2 trial of the drugs Sofosbuvir and Ribavirin revealed that this curing combination gives patients with Hepatitis C a viable treatment that is tolerable and effectively clears the virus. The study[…]
Daclatasvir and Asunaprevir are a Promising Oral Treatment for Patients with the Hepatitis C Virus
Antiviral, Drug Research & Development API Tags: Hepatitis Cribavirin Apr 29, 2013
The Hepatitis C virus is daunting in nature, affecting 180 million people worldwide and a little over 4 million people in the United States. As the leading cause of chronic liver disease, which often leads to liver cancer, hepatitis C is currently difficult to treat with success. The typical treatment for patients with hepatitis C[…]
West Nile Virus Cases Show a 35% Increase in One Week
Anti-Retroviral / Anti-HIV, Antiviral, Bulk Active Ingredient, Cardiovascular Agent, Drug Research & Development API, TEVA API Tags: Australiaribavirin Sep 13, 2012
The CDC announced on Tuesday September 13, 2012 that the West Nile virus outbreak, which recently hit the U.S., is showing no signs of relenting, with an astounding 35% increase in cases from last week. With 2,636 cases involving people, including 118 deaths, all states except Alaska and Hawaii have reported at least one case[…]